ANIP
ANI Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Señales de momentum (gestores comparables):
amplitud de titulares +30.0% ·
flujo de acciones +3.1% ·
nuevas posiciones netas +20.0%
— fórmula
Acumulación amplia — aumento de acciones entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 102 | +1 | 15.27M | $1.21B | +7 | −5 |
| Q1 2026 | 103 | -4 | 30.24M | $1.11B | +4 | −9 |
| Q4 2025 | 108 | 0 | 15.43M | $1.15B | +1 | — |
| Q3 2025 | 20 | +5 | 7.92M | $725.10M | +5 | −1 |
| Q2 2025 | 13 | -1 | 6.82M | $445.05M | — | −1 |
| Q1 2025 | 11 | +3 | 3.19M | $213.52M | +3 | — |
| Q4 2024 | 8 | -2 | 3.16M | $174.48M | — | −2 |
| Q3 2024 | 9 | -3 | 1.88M | $111.88M | — | −3 |
| Q2 2024 | 12 | — | 1.26M | $80.52M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (pasivo) | 2.55M | -1.2% | $233.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (pasivo) | 1.28M | 0.0% | $117.02M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (pasivo) | 711.71K | -0.6% | $65.19M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 580.09K | +1.8% | $53.14M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 5 | Geode Capital Management ✦ (pasivo) | 458.01K | +7.1% | $41.96M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 399.09K | Nuevo | $36.56M | 0.1% | New | 1 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 379.03K | — | $34.72M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Arrowstreet Capital ✦ | 360.18K | Nuevo | $32.99M | 0.0% | New | 1 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 272.90K | +112.6% | $25.00M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 258.19K | — | $23.65M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 11 | Morgan Stanley ✦ | 232.03K | — | $21.25M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 12 | D. E. Shaw & Co. ✦ | 213.01K | +211.9% | $19.51M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Millennium Management ✦ | 65.25K | -93.5% | $5.98M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 53.78K | Nuevo | $4.93M | 0.0% | New | 1 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 35.09K | +865.5% | $3.21M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 16 | Marshall Wace ✦ | 30.19K | Nuevo | $2.77M | 0.0% | New | 1 | SEC ↗ ×2 |
| 17 | AQR Capital Management ✦ | 14.48K | -22.1% | $1.33M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 18 | T. Rowe Price ✦ | 9.70K | +5.2% | $889,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 8.59K | Nuevo | $786,661 | 0.0% | New | 1 | SEC ↗ |
| 20 | Wellington Management ✦ | 8.17K | +3.7% | $748,556 | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Point72 Asset Management | $36.56M | 0.1% |
| Arrowstreet Capital | $32.99M | 0.0% |
| Two Sigma Investments | $4.93M | 0.0% |
| Marshall Wace | $2.77M | 0.0% |
| Gotham Asset Management | $786,661 | 0.0% |
Posición cerrada
| Norges Bank | $625,421 | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 4 tenedores, 27.49M acciones, $50.55M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 2.85K acc. · $208,050
Officer, Director · 5.40K acc. · $383,400
Officer · 500 acc. · $35,395
Director · 1.00K acc. · $71,530
Officer · 2.85K acc. · $207,480
Officer, Director · 5.40K acc. · $401,220
Officer · 500 acc. · $37,740
Officer · 3.16K acc. · $243,474
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología